Futura Medical PLC
LSE:FUM
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.02
31
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| UK |
|
Futura Medical PLC
LSE:FUM
|
7.8m GBP |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
954.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
546.2B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
268.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.9B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
219B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
265.4B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
147.6B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
94.4B EUR |
Loading...
|
Market Distribution
| Min | -195 650% |
| 30th Percentile | 0% |
| Median | 0.1% |
| 70th Percentile | 0.2% |
| Max | 4 630.7% |
Other Profitability Ratios
Futura Medical PLC
Glance View
Futura Medical Plc is a pharmaceutical group that develops products for both the prescription and consumer healthcare markets. The company is headquartered in Guildford, Surrey and currently employs 13 full-time employees. The company went IPO on 2006-07-10. The firm is focused on developing a portfolio of products based on its transdermal DermaSys technology. Its patented transdermal DermaSys technology provides rapid and targeted local delivery of medical treatments via the skin. The firm is engaged in developing a portfolio of products for therapeutic areas, such as sexual health, including erectile dysfunction, and pain relief. The firm's products include MED3000 and TPR100. The firm's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The firm has conducted a Phase III study using MED3000 in ED. TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Futura Medical PLC is -28.3%, which is above its 3-year median of -129%.
Over the last 2 years, Futura Medical PLC’s Operating Margin has increased from -351% to -28.3%. During this period, it reached a low of -351% on Jun 30, 2023 and a high of 8.9% on Dec 31, 2024.